Needham analyst Joseph Stringer maintained a Buy rating on Stoke Therapeutics today and set a price target of $40.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Stringer has given his Buy rating due to a combination of factors including the strength of Stoke Therapeutics’ lead asset, zorevunersen, in Dravet Syndrome. He highlights four-year open-label extension data showing durable seizure reductions alongside ongoing gains in cognition and behavior across key Vineland-3 domains, which he believes meaningfully reinforce the therapy’s potential as a disease-modifying treatment.
He further notes that the pivotal Phase 3 EMPEROR study is progressing well, with most of the target ~150 patients already randomized and no discontinuations observed, supporting confidence in trial execution and data reliability. With enrollment expected to finish soon and a clear path to mid-2027 topline results, he views the unchanged $40 price target as justified by the robust clinical profile, favorable risk/reward, and long-term value creation potential for Stoke’s Dravet program.
According to TipRanks, Stringer is a 5-star analyst with an average return of 24.6% and a 48.07% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Stoke Therapeutics, and Shattuck Labs.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $38.00 price target.